We have presented the first detailed cancer-related and breast cancer-specific PROs of a randomized clinical trial comparing NCT vs. NET in premenopausal patients with estrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Here, ERBB2 is linked to cancer.